1. Home
  2. SYBX vs SYNX Comparison

SYBX vs SYNX Comparison

Compare SYBX & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • SYNX
  • Stock Information
  • Founded
  • SYBX N/A
  • SYNX 2005
  • Country
  • SYBX United States
  • SYNX Israel
  • Employees
  • SYBX N/A
  • SYNX N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • SYNX
  • Sector
  • SYBX Health Care
  • SYNX
  • Exchange
  • SYBX Nasdaq
  • SYNX Nasdaq
  • Market Cap
  • SYBX 13.6M
  • SYNX 13.7M
  • IPO Year
  • SYBX N/A
  • SYNX 2024
  • Fundamental
  • Price
  • SYBX $1.26
  • SYNX $1.74
  • Analyst Decision
  • SYBX
  • SYNX
  • Analyst Count
  • SYBX 0
  • SYNX 0
  • Target Price
  • SYBX N/A
  • SYNX N/A
  • AVG Volume (30 Days)
  • SYBX 7.8K
  • SYNX 127.8K
  • Earning Date
  • SYBX 08-07-2025
  • SYNX 05-14-2025
  • Dividend Yield
  • SYBX N/A
  • SYNX N/A
  • EPS Growth
  • SYBX N/A
  • SYNX N/A
  • EPS
  • SYBX 0.21
  • SYNX N/A
  • Revenue
  • SYBX N/A
  • SYNX $9,094,000.00
  • Revenue This Year
  • SYBX N/A
  • SYNX $32.35
  • Revenue Next Year
  • SYBX N/A
  • SYNX N/A
  • P/E Ratio
  • SYBX $5.82
  • SYNX N/A
  • Revenue Growth
  • SYBX N/A
  • SYNX 19.14
  • 52 Week Low
  • SYBX $0.90
  • SYNX $1.65
  • 52 Week High
  • SYBX $1.88
  • SYNX $6.49
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 52.81
  • SYNX 48.15
  • Support Level
  • SYBX $1.17
  • SYNX $1.67
  • Resistance Level
  • SYBX $1.27
  • SYNX $1.91
  • Average True Range (ATR)
  • SYBX 0.04
  • SYNX 0.20
  • MACD
  • SYBX -0.01
  • SYNX 0.02
  • Stochastic Oscillator
  • SYBX 40.00
  • SYNX 22.21

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: